CHRNA7 and Cognitive impairment: A recent review stated that α7nAChR-agonists induce beneficial effects in patients with psychiatric disorders (139) ameliorating cognitive deficits, negative symptoms, and sensory gating disturbances in both preclinical and clinical trials of schizophrenia (139, 157–161).